Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Genmab : EC Approves Expanded Darzalex Use in Multiple Myeloma

share with twitter share with LinkedIn share with facebook
share via e-mail
11/19/2019 | 11:41am EST

By Colin Kellaher

Genmab A/S (GMAB.KO, GMAB) on Tuesday said the European Commission approved the expanded use of Darzalex in a form of the blood cancer multiple myeloma.

The Copenhagen biotechnology company said the EC granted marketing authorization for Darzalex in combination with lenalidomide and dexamethasone for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplant.

Johnson & Johnson's (JNJ) Janssen Biotech Inc. unit has an exclusive license to develop, manufacture and commercialize Darzalex under an August 2012 agreement with Genmab.

The European Medicines Agency's Committee for Medicinal Products for Human Use last month recommended approval of the additional indication.

Write to Colin Kellaher at colin.kellaher@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
GENMAB A/S -1.53% 1644.5 Delayed Quote.13.09%
JOHNSON & JOHNSON -0.45% 143.8095 Delayed Quote.0.03%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on JOHNSON & JOHNSON
03:16pJOHNSON & JOHNSON : to Participate in Barclays Global Healthcare Conference
PR
07:54aJOHNSON & JOHNSON : Launches Heartline the First-of-its-Kind Virtual Study desig..
AQ
02/25Apple, J&J to study if Apple Watch app leads to lower stroke risk
RE
02/25APPLE : J&J Opens Enrollment for 'Heartline' Study in Collaboration With Apple
DJ
02/25JOHNSON & JOHNSON : Launches Heartline™, the First-of-its-Kind, Virtual St..
PR
02/24J&J, Sanofi, Inovio Hunt for Coronavirus Vaccines
DJ
02/24JOHNSON & JOHNSON : Ex-dividend day for
FA
02/19JOHNSON & JOHNSON : to Expand Partnership with U.S. Department of Health and Hum..
AQ
02/19JOHNSON & JOHNSON : to Participate in Cowen 40th Annual Health Care Conference
AQ
02/18JOHNSON & JOHNSON : MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATION..
AQ
More news
Financials (USD)
Sales 2020 85 861 M
EBIT 2020 27 634 M
Net income 2020 19 976 M
Finance 2020 322 M
Yield 2020 2,77%
P/E ratio 2020 19,6x
P/E ratio 2021 16,6x
EV / Sales2020 4,43x
EV / Sales2021 4,18x
Capitalization 381 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 159,47  $
Last Close Price 144,65  $
Spread / Highest target 19,6%
Spread / Average Target 10,2%
Spread / Lowest Target -8,05%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON0.03%381 112
ROCHE HOLDING AG5.13%287 430
MERCK AND COMPANY-11.74%204 366
NOVARTIS-5.57%201 414
PFIZER-11.51%187 773
NOVO NORDISK AS8.92%144 260